185 related articles for article (PubMed ID: 36712071)
21. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin Oyarzún CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
22.
Xiao P; Dolinska M; Sandhow L; Kondo M; Johansson AS; Bouderlique T; Zhao Y; Li X; Dimitriou M; Rassidakis GZ; Hellström-Lindberg E; Minato N; Walfridsson J; Scadden DT; Sigvardsson M; Qian H
Blood Adv; 2018 Mar; 2(5):534-548. PubMed ID: 29514790
[TBL] [Abstract][Full Text] [Related]
23. ENKUR Is Involved in the Regulation of Cellular Biology in Colorectal Cancer Cells via PI3K/Akt Signaling Pathway.
Ma Q; Lu Y; Gu Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819841433. PubMed ID: 30947633
[TBL] [Abstract][Full Text] [Related]
24. Myeloproliferative disorders and their effects on bone homeostasis: the role of megakaryocytes.
Karagianni A; Ravid K
Blood; 2022 May; 139(21):3127-3137. PubMed ID: 34428274
[TBL] [Abstract][Full Text] [Related]
25. Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients.
Sirinukunwattana K; Aberdeen A; Theissen H; Sousos N; Psaila B; Mead AJ; Turner GDH; Rees G; Rittscher J; Royston D
Blood Adv; 2020 Jul; 4(14):3284-3294. PubMed ID: 32706893
[TBL] [Abstract][Full Text] [Related]
26. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
27. Endoplasmic reticulum stress induced apoptosis and caspase activation is mediated through mitochondria during megakaryocyte differentiation.
Kovuru N; Raghuwanshi S; Sharma DS; Dahariya S; Pallepati A; Gutti RK
Mitochondrion; 2020 Jan; 50():115-120. PubMed ID: 31669618
[TBL] [Abstract][Full Text] [Related]
28. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
29. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Wang JC; Kundra A; Andrei M; Baptiste S; Chen C; Wong C; Sindhu H
Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
[TBL] [Abstract][Full Text] [Related]
30. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
31. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.
Mager LF; Riether C; Schürch CM; Banz Y; Wasmer MH; Stuber R; Theocharides AP; Li X; Xia Y; Saito H; Nakae S; Baerlocher GM; Manz MG; McCoy KD; Macpherson AJ; Ochsenbein AF; Beutler B; Krebs P
J Clin Invest; 2015 Jul; 125(7):2579-91. PubMed ID: 26011644
[TBL] [Abstract][Full Text] [Related]
32. Crucial role for endoplasmic reticulum stress during megakaryocyte maturation.
Lopez JJ; Palazzo A; Chaabane C; Albarran L; Polidano E; Lebozec K; Dally S; Nurden P; Enouf J; Debili N; Bobe R
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2750-8. PubMed ID: 24115034
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms.
Bekendam RH; Ravid K
Front Cell Dev Biol; 2023; 11():1207395. PubMed ID: 37457287
[TBL] [Abstract][Full Text] [Related]
34. Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis.
Guo BB; Linden MD; Fuller KA; Phillips M; Mirzai B; Wilson L; Chuah H; Liang J; Howman R; Grove CS; Malherbe JA; Leahy MF; Allcock RJ; Erber WN
Br J Haematol; 2020 Jan; 188(2):272-282. PubMed ID: 31426129
[TBL] [Abstract][Full Text] [Related]
35. Proteostasis alterations in myeloproliferative neoplasms: Oncogenic relevance and therapeutic opportunities.
Santiago-Fernández O; Osorio FG; López-Otín C
Exp Hematol; 2016 Jul; 44(7):574-7. PubMed ID: 27090962
[TBL] [Abstract][Full Text] [Related]
36. Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic Differentiation.
Salati S; Prudente Z; Genovese E; Pennucci V; Rontauroli S; Bartalucci N; Mannarelli C; Ruberti S; Zini R; Rossi C; Bianchi E; Guglielmelli P; Tagliafico E; Vannucchi AM; Manfredini R
Stem Cells Dev; 2018 Feb; 27(4):225-236. PubMed ID: 29258411
[TBL] [Abstract][Full Text] [Related]
37. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
Büttner-Herold M; Sticht C; Wiech T; Porubsky S
Histopathology; 2021 Apr; 78(5):738-748. PubMed ID: 33078472
[TBL] [Abstract][Full Text] [Related]
38. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
39. Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms.
Malherbe JA; Fuller KA; Arshad A; Nangalia J; Romeo G; Hall SL; Meehan KS; Guo B; Howman R; Erber WN
J Clin Pathol; 2016 Feb; 69(2):155-63. PubMed ID: 26290261
[TBL] [Abstract][Full Text] [Related]
40. The Analysis of the Human Megakaryocyte and Platelet Coding Transcriptome in Healthy and Diseased Subjects.
De Wispelaere K; Freson K
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
